Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Real-time Estimate Cboe Europe Other stock markets 10:43:33 2024-06-10 am EDT			5-day change	1st Jan Change
1,620 ^GBX	-0.52%		+1.25%	+11.57%

01:38pm	GSK Says FDA Approved RSV Vaccine's Expanded Age Indication	MT
12:30pm	Moderna COVID/flu combo vaccine superior to separate shots in trial	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk \| GSK	03:42am	AQ
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk	Jun. 07	BU
GSK : DO NOT COURIER US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk	Jun. 07	PU
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies \| GSK	Jun. 07	AQ
GSK : accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies	Jun. 06	PU
Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer \| GSK	Jun. 04	AQ
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer - Form 6-K	Jun. 03	PU
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	Jun. 03	BU
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	Jun. 03	PU
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma - Form 6-K	Jun. 03	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling - Form 6-K	Jun. 03	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling \| GSK	Jun. 03	AQ
Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma \| GSK	Jun. 03	AQ
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	Jun. 02	PU
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	Jun. 02	BU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	May. 29	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases - Form 6-K	May. 24	PU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	May. 24	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases \| GSK	May. 24	AQ
GSK : New data at ASCO showcases the transformational potential of GSK's oncology portfolio	May. 23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : Frightened markets create an entry opportunity in GSK

June 04, 2024 at 08:38 am EDT

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT